Premium
Use of glycoprotein IIb/IIIa inhibitors in unstable angina and non‐ST‐elevation myocardial infarction
Author(s) -
Crosbie Deanne J
Publication year - 2005
Publication title -
emergency medicine australasia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.602
H-Index - 52
eISSN - 1742-6723
pISSN - 1742-6731
DOI - 10.1111/j.1742-6723.2005.00783.x
Subject(s) - medicine , unstable angina , thrombus , myocardial infarction , acute coronary syndrome , cardiology , platelet , glycoprotein , coronary thrombosis , thrombosis , platelet membrane glycoprotein , biology , microbiology and biotechnology
Acute coronary syndromes (ACS) are a major cause of morbidity and mortality in Western society. The commonest underlying pathology is the coronary atherosclerotic plaque complicated by thrombosis. Platelets play a central role. As the glycoprotein IIb/IIIa receptor is involved in the final step of platelet thrombus formation development and investigation of its blockage in ACS is at the fore. Initial hospital management of ACS occur in the ED setting. The present article outlines the above topics and clarifies the place of glycoprotein IIb/IIIa receptor inhibition in ED.